Jafron Biomedical Co Ltd (300529) - Net Assets

Latest as of March 2026: CN¥3.70 Billion CNY ≈ $541.36 Million USD

Based on the latest financial reports, Jafron Biomedical Co Ltd (300529) has net assets worth CN¥3.70 Billion CNY (≈ $541.36 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.52 Billion ≈ $807.93 Million USD) and total liabilities (CN¥1.82 Billion ≈ $266.57 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Jafron Biomedical Co Ltd to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥3.70 Billion
% of Total Assets	67.01%
Annual Growth Rate	21.96%
5-Year Change	2.59%
10-Year Change	193.17%
Growth Volatility	26.78

Jafron Biomedical Co Ltd - Net Assets Trend (2011–2025)

This chart illustrates how Jafron Biomedical Co Ltd's net assets have evolved over time, based on quarterly financial data. See how many days can Jafron Biomedical Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Jafron Biomedical Co Ltd (2011–2025)

The table below shows the annual net assets of Jafron Biomedical Co Ltd from 2011 to 2025. For live valuation and market cap data, see 300529 stock market capitalisation.

Year	Net Assets	Change
2025-12-31	CN¥3.47 Billion ≈ $507.96 Million	+4.10%
2024-12-31	CN¥3.33 Billion ≈ $487.97 Million	+5.77%
2023-12-31	CN¥3.15 Billion ≈ $461.36 Million	-12.19%
2022-12-31	CN¥3.59 Billion ≈ $525.40 Million	+6.11%
2021-12-31	CN¥3.38 Billion ≈ $495.13 Million	+19.41%
2020-12-31	CN¥2.83 Billion ≈ $414.65 Million	+30.55%
2019-12-31	CN¥2.17 Billion ≈ $317.62 Million	+26.05%
2018-12-31	CN¥1.72 Billion ≈ $251.97 Million	+23.75%
2017-12-31	CN¥1.39 Billion ≈ $203.62 Million	+17.52%
2016-12-31	CN¥1.18 Billion ≈ $173.26 Million	+109.92%
2015-12-31	CN¥564.06 Million ≈ $82.54 Million	+24.68%
2014-12-31	CN¥452.42 Million ≈ $66.20 Million	+19.02%
2013-12-31	CN¥380.12 Million ≈ $55.62 Million	+30.70%
2012-12-31	CN¥290.84 Million ≈ $42.56 Million	+34.92%
2011-12-31	CN¥215.57 Million ≈ $31.54 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Jafron Biomedical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 3457.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥2.43 Billion	69.93%
Other Components	CN¥1.04 Billion	30.07%
Total Equity	CN¥3.47 Billion	100.00%

Jafron Biomedical Co Ltd Competitors by Market Cap

The table below lists competitors of Jafron Biomedical Co Ltd ranked by their market capitalization.

Company	Market Cap
Xi An Triangle Defens Co Ltd SHE:300775	$1.84 Billion
Telecom Argentina S.A F:TEO	$1.84 Billion
Guodian Nanjing Automation Co Ltd SHG:600268	$1.84 Billion
Shanghai Electric Wind Power Group Co. Ltd. A SHG:688660	$1.84 Billion
Costamare Inc NYSE:CMRE	$1.83 Billion
Lianhe Chemical Technology Co Ltd SHE:002250	$1.83 Billion
Wuxi Dk Electronic Materials Co Ltd SHE:300842	$1.83 Billion
Farglory Land Development Co Ltd TW:5522	$1.83 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jafron Biomedical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 3,333,906,225 to 3,471,717,244, a change of 137,811,019 (4.1%).
Net income of 532,821,312 contributed positively to equity growth.
Dividend payments of 643,568,950 reduced retained earnings.
Other comprehensive income decreased equity by 119,687,438.
Other factors increased equity by 368,246,095.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥532.82 Million	+15.35%
Dividends Paid	CN¥643.57 Million	-18.54%
Other Comprehensive Income	CN¥-119.69 Million	-3.45%
Other Changes	CN¥368.25 Million	+10.61%
Total Change	CN¥-	4.13%

Book Value vs Market Value Analysis

This analysis compares Jafron Biomedical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.61x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 51.26x to 3.61x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2011-12-31	CN¥0.31	CN¥15.70	x
2012-12-31	CN¥0.41	CN¥15.70	x
2013-12-31	CN¥0.54	CN¥15.70	x
2014-12-31	CN¥0.64	CN¥15.70	x
2015-12-31	CN¥0.80	CN¥15.70	x
2016-12-31	CN¥1.60	CN¥15.70	x
2017-12-31	CN¥1.78	CN¥15.70	x
2018-12-31	CN¥2.16	CN¥15.70	x
2019-12-31	CN¥2.71	CN¥15.70	x
2020-12-31	CN¥3.46	CN¥15.70	x
2021-12-31	CN¥4.18	CN¥15.70	x
2022-12-31	CN¥4.48	CN¥15.70	x
2023-12-31	CN¥3.97	CN¥15.70	x
2024-12-31	CN¥4.35	CN¥15.70	x
2025-12-31	CN¥4.35	CN¥15.70	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jafron Biomedical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 15.35%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 26.48%
• Asset Turnover: 0.37x
• Equity Multiplier: 1.56x
Recent ROE (15.35%) is below the historical average (27.14%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	35.15%	38.86%	0.79x	1.14x	CN¥54.21 Million
2012	34.39%	39.91%	0.73x	1.17x	CN¥70.94 Million
2013	33.35%	41.76%	0.66x	1.21x	CN¥88.77 Million
2014	35.38%	43.15%	0.69x	1.19x	CN¥114.81 Million
2015	35.54%	39.39%	0.74x	1.22x	CN¥144.03 Million
2016	17.07%	37.18%	0.42x	1.10x	CN¥83.71 Million
2017	20.45%	39.58%	0.42x	1.22x	CN¥145.31 Million
2018	23.67%	39.55%	0.50x	1.21x	CN¥232.13 Million
2019	26.64%	39.87%	0.57x	1.16x	CN¥356.58 Million
2020	31.18%	44.87%	0.61x	1.15x	CN¥594.56 Million
2021	35.63%	44.73%	0.56x	1.43x	CN¥860.93 Million
2022	24.89%	35.70%	0.46x	1.51x	CN¥532.14 Million
2023	13.87%	22.71%	0.35x	1.76x	CN¥121.74 Million
2024	24.60%	30.63%	0.50x	1.61x	CN¥486.80 Million
2025	15.35%	26.48%	0.37x	1.56x	CN¥185.65 Million

Industry Comparison

This section compares Jafron Biomedical Co Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $1,337,671,338
Average return on equity (ROE) among peers: 16.49%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Jafron Biomedical Co Ltd (300529)	CN¥3.70 Billion	35.15%	0.49x	$1.83 Billion
Shanghai Kehua Bio-Engineering Co Ltd (002022)	$1.09 Billion	22.08%	0.18x	$371.06 Million
Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223)	$154.18 Million	20.46%	1.55x	$3.63 Billion
Double Medical Technology Inc (002901)	$2.59 Billion	26.01%	0.31x	$2.56 Billion
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)	$115.39 Million	30.85%	0.16x	$506.97 Million
Lepu Medical Tech Beijing (300003)	$2.89 Billion	12.49%	0.08x	$3.19 Billion
INKON Life Technology Co Ltd (300143)	$2.07 Billion	2.43%	0.27x	$764.39 Million
Edan Instruments Inc (300206)	$1.16 Billion	1.16%	0.17x	$1.15 Billion
Guangdong Biolight Meditech Co Ltd (300246)	$89.93 Million	36.68%	0.42x	$735.30 Million
Beijing Leadman Biochemistry Co Ltd (300289)	$1.98 Billion	1.13%	0.19x	$467.29 Million
Sinocare Inc (300298)	$1.24 Billion	11.58%	0.08x	$1.17 Billion

About Jafron Biomedical Co Ltd

SHE:300529 China Medical Devices

Market Cap

$1.83 Billion

CN¥12.54 Billion CNY

Market Cap Rank

#6604 Global

#1444 in China

Share Price

CN¥15.70

Change (1 day)

-0.63%

52-Week Range

CN¥15.70 - CN¥24.54

All Time High

CN¥96.12